ZHEJIANG SUNFLOWER GREAT HEALTH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.28 CNY | +0.44% |
|
+5.07% | -25.00% |
| Sales 2022 | 336M 46.35M 63.37M | Sales 2023 | 338M 46.7M 63.85M | Capitalization | 3.91B 540M 738M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -138K -189K | Net income 2023 | 21M 2.9M 3.96M | EV / Sales 2022 | 10.3 x |
| Net cash position 2022 | 200M 27.61M 37.75M | Net cash position 2023 | 832M 115M 157M | EV / Sales 2023 | 9.11 x |
| P/E ratio 2022 |
-3,260
x | P/E ratio 2023 |
179
x | Employees | 319 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 23.6% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.44% | ||
| 1 week | +5.07% | ||
| Current month | -9.16% | ||
| 1 month | -8.80% | ||
| 3 months | -19.72% | ||
| 6 months | -20.28% | ||
| Current year | -25.00% |
1 week
2.11
2.32
1 month
2.102.60
Current year
1.833.15
1 year
1.833.61
3 years
1.834.59
5 years
1.826.65
10 years
1.8212.29
| Managers | Title | Age | Since |
|---|---|---|---|
Hua Xin Shi
CEO | Chief Executive Officer | 56 | 16-10-18 |
Wei Biao Pan
DFI | Director of Finance/CFO | 54 | 19-07-07 |
Lan Li
SEC | Corporate Secretary | 41 | 15-06-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Wu
BRD | Director/Board Member | 47 | 15-04-02 |
Lan Li
SEC | Corporate Secretary | 41 | 15-06-18 |
Yang Cao
CHM | Chairman | 51 | 19-11-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.28 | +0.44% | 13,398,470 |
| 24-04-25 | 2.27 | +0.89% | 13,904,800 |
| 24-04-24 | 2.25 | +2.27% | 14,828,970 |
| 24-04-23 | 2.2 | +1.85% | 10,524,660 |
| 24-04-22 | 2.16 | -0.46% | 9,858,500 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Zhejiang Sunflower Great Health Co Ltd, formerly Zhejiang Sunflower Great Health LLC, is a China-based company principally engaged in pharmaceutical manufacturing. The Company's main business is the research and development, production, and sales of anti infective, cardiovascular, and digestive system drugs. The Company's main products include clarithromycin raw materials, clarithromycin tablets, azithromycin dispersible tablets, azithromycin for injection, and erythromycin capsules. The Company's products are mainly used to treat infectious diseases, cardiovascular diseases, and digestive system diseases. The Company mainly conducts its business in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -25.00% | 405M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 300111 Stock
